Effects of empagliflozin in patients at risk of heart failure: the empire prevent metabolic trial - Takeaways - MDSpire

Effects of empagliflozin in patients at risk of heart failure: the empire prevent metabolic trial

  • By

  • Camilla Fuchs Andersen

  • Julie Hempel Larsen

  • Massar Omar

  • Nina Nouhravesh

  • Caroline Michaela Kistorp

  • Christian Tuxen

  • Filip K Knop

  • Per Lav Madsen

  • Julie Lyng Forman

  • Filip Søskov Davidovski

  • Lars Køber

  • Morten Schou

  • Jacob Eifer Møller

  • Jesper Jensen

  • January 8, 2026

  • 0 min

Share

  • 1

    Empagliflozin significantly reduced estimated extracellular volume (eECV) in overweight patients at risk of heart failure compared to placebo.

  • 2

    The study involved 191 non-diabetic patients with a median age of 68 years and median BMI of 31.9 kg/m2.

  • 3

    Empagliflozin did not significantly affect epicardial adipose tissue (EAT) mass after 180 days of treatment.

  • 4

    The trial was randomized, double-blind, and placebo-controlled, aiming to evaluate empagliflozin's potential for heart failure prevention.

  • 5

    Few patients experienced side effects, indicating that empagliflozin was safe for use in the studied population.

Original Source(s)

Effects of empagliflozin in patients at risk of heart failure: the empire prevent metabolic trial

  • by Camilla Fuchs Andersen, Julie Hempel Larsen, Massar Omar, Nina Nouhravesh, Caroline Michaela Kistorp, Christian Tuxen, Filip K Knop, Per Lav Madsen, Julie Lyng Forman, Filip Søskov Davidovski, Lars Køber, Morten Schou, Jacob Eifer Møller, Jesper Jensen

  • January 8, 2026

Related Content

Analysis of factors associated with cognitive impairment in elderly patients hospitalized with chronic heart failure

Grip Strength Plus Waist Size May Flag Risk T2D Risk

Researchers found that patients with higher waist circumference and lower grip strength had the greatest risk for developing type 2 diabetes during long-term follow-up.

AD Not Linked to Early CV Risk Markers

Repeated assessments from childhood to early adulthood did not identify consistent cardiometabolic risk patterns by disease activity or severity.